1. Home
  2. FWRG vs ZVRA Comparison

FWRG vs ZVRA Comparison

Compare FWRG & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Watch Restaurant Group Inc.

FWRG

First Watch Restaurant Group Inc.

HOLD

Current Price

$11.08

Market Cap

648.6M

ML Signal

HOLD

Logo Zevra Therapeutics Inc.

ZVRA

Zevra Therapeutics Inc.

HOLD

Current Price

$9.54

Market Cap

689.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FWRG
ZVRA
Founded
1983
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
648.6M
689.4M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
FWRG
ZVRA
Price
$11.08
$9.54
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
9
Target Price
$18.50
★ $25.25
AVG Volume (30 Days)
★ 1.5M
767.7K
Earning Date
11-03-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
3.33
★ 159.21
EPS
N/A
★ 0.74
Revenue
★ $1,222,501,000.00
$106,470,000.00
Revenue This Year
$13.58
$43.97
Revenue Next Year
$11.63
$15.93
P/E Ratio
★ N/A
$13.26
Revenue Growth
20.34
★ 350.91
52 Week Low
$9.88
$8.01
52 Week High
$18.77
$15.04

Technical Indicators

Market Signals
Indicator
FWRG
ZVRA
Relative Strength Index (RSI) 46.16 33.16
Support Level $10.22 $9.29
Resistance Level $12.86 $11.19
Average True Range (ATR) 0.61 0.46
MACD -0.01 -0.06
Stochastic Oscillator 28.14 1.53

Price Performance

Historical Comparison
FWRG
ZVRA

About FWRG First Watch Restaurant Group Inc.

First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. The company generates revenues from Restaurant sales and Franchise revenues. It generates maximum revenue from Restaurant sales.

About ZVRA Zevra Therapeutics Inc.

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Share on Social Networks: